FDA approvals of specialty drugs, 2000-2024
Health Affairs Scholar · 04.02.2026 · 4 (2)
DOI: 10.1093/haschl/qxag035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs Scholar, online erschienen am 07.02.2026. Verfasst von Sophie E Knox und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, M…. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sophie E Knox, Mpharm, Claire H Brennan, BA, Daniel E Enright, MS, Peter J Neumann, ScD, James D Chambers, PhD; FDA Approvals of Specialty Drugs, 2000-2024
Autor:innen und Institutionen
- The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, United States.
ORCID-Profile: Claire H Brennan, Peter J Neumann, James D Chambers
Zitieren
APA
Knox, S. E., Brennan, C. H., Enright, D. E., Neumann, P. J., & Chambers, J. D. (2026). FDA approvals of specialty drugs, 2000-2024. Health Affairs Scholar, 4(2). https://doi.org/10.1093/haschl/qxag035
Vancouver
Knox SE, Brennan CH, Enright DE, Neumann PJ, Chambers JD. FDA approvals of specialty drugs, 2000-2024. Health Affairs Scholar. 2026;4(2). doi:10.1093/haschl/qxag035
BibTeX
@article{Knox2026,
author = {Knox, Sophie E and Brennan, Claire H and Enright, Daniel E and Neumann, Peter J and Chambers, James D},
title = {FDA approvals of specialty drugs, 2000-2024},
journal = {Health Affairs Scholar},
year = {2026},
volume = {4},
number = {2},
doi = {10.1093/haschl/qxag035}
}
EUVIMED